## Additional Questions and Answers to the RFP No. NIH-NIAID-DMID-PR2004-02

## 'Recombinant Type E Botulinum Neurotoxin Vaccine'

The referenced RFP is hereby modified as follows:

Section I.2. <u>Authorized Substitutions of Clauses</u> is revised to add FAR Clause 52.215-20, Requirements for Cost or Pricing Data or Information Other Than Cost or Pricing Data.

Section I.3. <u>Additional Contract Clauses</u> is revised to remove item (6) FAR 52.237-10, Indemnification of Uncompensated Overtime (OCTOBER 1997).

Section M. <u>Evaluation Factors for Award</u>, item 3. <u>Technical Evaluation Criteria</u>, is hereby revised to remove the sentence 'Because there is no competition, weights have not been assigned for evaluation purposes.'

Below are additional questions and answers:

Q14. Page 12 of 29 - The maximum page limitation for the technical and business volume combined is 50 pages. Based on the requirements in the RFP for both the technical and business volume, i.e. inclusion of most recent annual report (page 27 of 29), inclusion of travel policies of prime and subs (page 27 of 29), inclusion of subcontractor proposals in the same format as the prime (page 26 of 29), as well as the requirement to address each aspect of the statement of work and how each is to be accomplished (page 21 of 29), the 50 page limitation will immediately be exceeded, for each volume. Please advise how offerors should approach the page limitation.

Answer: The 50-page limit **applies** to both technical and business proposals. However, the Representations and Certifications and the Financial report which includes travel policies are excluded from the 50-page limitation.

Q15. The solicitation says that the offeror is to provide the vaccine material, i.e. the offeror has already developed a vaccine and has done the preclinical testing. Is this correct?

Answer: YES. The Government expects that the starting material (a recombinant type E botulinum neurotoxin vaccine) will be supplied by **the Offeror** and that the material will have demonstrated potency in a standardized mouse protection bioassay.